Sofinnova Crossover I - 23 Jul 2025 SCHEDULE 13D/A Report for Abivax SA Ordinary Shares, par value (euro)0.01 per share (ABVX)

Quoteable Key Fact

"Sofinnova Crossover I disclosed 11% ownership in Abivax SA Ordinary Shares, par value (euro)0.01 per share (ABVX) on 23 Jul 2025."

Quick Takeaways

Sofinnova Crossover I filed SCHEDULE 13D/A for Abivax SA Ordinary Shares, par value (euro)0.01 per share (ABVX).
Disclosed ownership: 11%.
Date of event: 23 Jul 2025.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Name	Ownership	Shares Owned	sole voting power	Signature	Title	CIK
Sofinnova Crossover I SLP	11%	9,599,478	9,599,478	/s/ Antoine Papiernik	Managing Partner	0001845105
Sofinnova Partners SAS	11%	9,599,478	9,599,478	/s/ Antoine Papiernik	Managing Partner	0001574139
Antoine Papiernik	11%	9,599,478	9,599,478	/s/ Antoine Papiernik	Antoine Papiernik	0001768408
Cedric Moreau	11%	9,599,478	9,599,478	/s/ Cedric Moreau	Cedric Moreau
Kinam Hong	11%	9,599,478	9,599,478	/s/ Kinam Hong	Kinam Hong
Joseph Anderson	11%	9,599,478	9,599,478	/s/ Joseph Anderson	Joseph Anderson
Jacques Theurillat	11%	9,599,478	9,599,478	/s/ Jacques Theurillat	Jacques Theurillat